The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...
Despite vaccines and treatments, SARS-CoV-2-the virus that causes COVID-19-continues to pose a global health threat, driven by new variants and its ability to hijack human cells in ways that still ...
UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...
A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting ...
Morning Overview on MSN
CDC flags BA.3.2 COVID variant after dozens of US detections
The Centers for Disease Control and Prevention has flagged a SARS-CoV-2 subvariant called BA.3.2 after identifying it in U.S. clinical samples and wastewater, adding to a growing international count ...
Interna Therapeutics, a clinical-stage biopharmaceutical company announced today that it has signed an agreement with the University of Oxford to conduct a Phase IIa human challenge trial evaluating ...
Microscope image of human epithelium cells (blue) infected with SARS-CoV-2 (red), showing the virus spreading from one cell to another. LA JOLLA, CA—Despite vaccines and treatments, SARS-CoV-2—the ...
Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 ...
Forget about locating molecules in the blink of an eye, which takes as long as a quarter second—far too long a time to distinguish a sequence of subcellular events. Instead, try doing what Stanford ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results